In enzymology, a corticosterone 18-monooxygenase (EC 1.14.15.5) is an enzyme that catalyzes the chemical reaction
| corticosterone 18-monooxygenase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| EC no. | 1.14.15.5 | ||||||||
| CAS no. | 37256-75-0 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| Gene Ontology | AmiGO / QuickGO | ||||||||
| |||||||||
- corticosterone + reduced adrenal ferredoxin + O2 18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O[1]
The 3 substrates of this enzyme are corticosterone, reduced adrenal ferredoxin, and O2, whereas its 3 products are 18-hydroxycorticosterone, oxidized adrenal ferredoxin, and H2O.[2]
This enzyme belongs to the family of oxidoreductases, specifically those acting on paired donors, with O2 as oxidant and incorporation or reduction of oxygen. The oxygen incorporated need not be derived from O2 with reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen into the other donor.[3][4] The systematic name of this enzyme class is corticosterone,reduced-adrenal-ferredoxin:oxygen oxidoreductase (18-hydroxylating). Other names in common use include corticosterone 18-hydroxylase, and corticosterone methyl oxidase. This enzyme participates in c21-steroid hormone metabolism.[5]
References
edit- ^ "ENZYME - 1.14.15.5 corticosterone 18-monooxygenase". enzyme.expasy.org. Archived from the original on 2022-08-20. Retrieved 2022-08-20.
- ^ "PhytoMine: GOTerm GO:0047783 corticosterone 18-monooxygenase activity GO". phytozome-next.jgi.doe.gov. Archived from the original on 2022-08-20. Retrieved 2022-08-20.
- ^ McDonald A (2019). "The Enzyme List Class 1 — Oxidoreductases" (PDF). Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. 1 (1). Ireland: 759. Archived (PDF) from the original on 2022-03-05. Retrieved 2022-08-20 – via Trinity College Dublin.
- ^ Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, et al. (September 2020). "Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase" (PDF). The Lancet. Diabetes & Endocrinology. 8 (9): 748–761. doi:10.1016/S2213-8587(20)30240-0. PMID 32730798. S2CID 220892722.
- ^ Yanagibashi K, Shackleton CH, Hall PF (June 1988). "Conversion of 11-deoxycorticosterone and corticosterone to aldosterone by cytochrome P-450 11 beta-/18-hydroxylase from porcine adrenal". Journal of Steroid Biochemistry. 29 (6): 665–675. doi:10.1016/0022-4731(88)90167-7. PMID 3386233.
